Long‐Term Treatment With Subcutaneous Treprostinil in Patients With Severe Inoperable Chronic Thromboembolic Pulmonary Hypertension in the Multimodal Therapy Era (Data From CTREPH Study Open Label Extension)

Documenti analoghi

• Subcutaneous Treprostinil in PH Associated With Left Heart Disease or Chronic Lung Disease
  di: Roela Sadushi‐Koliçi, et al.
  Pubblicazione: (2026)
• Real‐World Dosing and Persistence of Oral Treprostinil Initiation Strategies in Patients With Pulmonary Arterial Hypertension
  di: Daniel J. Lachant, et al.
  Pubblicazione: (2025)
• Treprostinil Is Associated With Early and Sustained Improvement in Group 3 Pulmonary Hypertension and Right Ventricular Function in Children
  di: Kaushik Parvathaneni, et al.
  Pubblicazione: (2026)
• Stress Echocardiography to Detect Exercise Pulmonary Hypertension in Patients With Chronic Thromboembolic Pulmonary Disease
  di: Adam Dhayyat, et al.
  Pubblicazione: (2026)
• Recognition, diagnosis, and operability assessment of chronic thromboembolic pulmonary hypertension (CTEPH): A global cross‐sectional scientific survey (CLARITY)
  di: Grzegorz Kopeć, et al.
  Pubblicazione: (2024)